Published June 6, 2017 This content is archived.
Presented by the UB Clinical and Translational Science Institute Drug Development Core
Case studies in drug discovery and pre-clinical development
Opportunities to become familiar with GLP and pre-clinical drug development programs
Regulatory compliance leading to IND application
Strategies for translation to Phase I study design
Who: UB CTSI Investigators with drug discovery and drug development research programs
Where: Roswell Park Cancer Institute, Zebro Conference Room
When: Monthly, 4 – 5 p.m., first Tuesday of each month (except July, second Tuesday)
Schedule:
Date | Presenter(s) | Topic |
6/6/17 | Andrei Gudkov, PhD, DSc | NAMPT Inhibitor OT-82 targeting energy metabolism in hematologic malignancies |
7/11/17 | Katerina Gurova, MD, PhD Joseph Skitzki, MD | Curaxins - Novel epigenetic anticancer drug |
8/1/17 | Ravindra Pandey, PhD Sandra Gollnick, PhD | New drug development perspectives in PDT |
9/5/17 | Lyudmila Burdelya, PhD Vadim Krivokrysenko, PhD | Entolimod as a dual use oncology biodefense drug |
10/3/17 | Robert Fenstermaker, MD | Anti-GBM vaccine |
Ellen Goldbaum
Senior Medical Editor
Office of University Communications
(716) 645-4605